The shares are listed on the NYSE

Davis Polk advised the sales agents in connection with a new SEC-registered at-the-marketing offering program by Emergent BioSolutions Inc. of its shares of common stock for up to an aggregate offering price of $150 million. The common stock is listed on the New York Stock Exchange under the symbol “EBS.”

Emergent BioSolutions is a life sciences company that provides solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that they develop and manufacture for governments and consumers. Emergent offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.

The Davis Polk capital markets team included partner Yasin Keshvargar and associates Christian Knoble and Sierra M. Acosta. Partner David R. Bauer and associate Adrian Rabin provided intellectual property advice. The tax team included partner Kara L. Mungovan and associates Eitan Ulmer and Ted Lee. All members of the Davis Polk team are based in the New York office.

Copy link to share post